Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00538798 · ClinicalTrials.gov registry record · Phase 1
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00538798 is a Phase 1 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 50 participants.
The verdict
NCT00538798, a Phase 1 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[18F\]SP203.
Interventions
- DRUG [18F]SP203
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-09-28 |
| Est. Completion | 2015-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00538798
The ClinicalTrials.gov registry entry for NCT00538798 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]SP203 is the first listed.
NCT00538798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00538798 about?
NCT00538798 is a clinical study titled "PET Imaging of Brain mGluR5 Receptors Using [18F]SP203". The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[...
What is the current status of trial NCT00538798?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2007-09-28. Estimated completion is 2015-03-17.
What interventions are being tested in trial NCT00538798?
The interventions under investigation include: [18F]SP203 (DRUG).
Who is sponsoring clinical trial NCT00538798?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.